anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Adrenal insufficiency in patients with classic 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH) is treated with glucocorticoid replacement therapy. Control of adrenal-derived androgen excess usually requires supraphysiologic glucocorticoid dosing, which predisposes patients to glucocorticoid-related complications. Crinecerfont, an oral corticotropin-releasing factor type 1 receptor antagonist, lowered androstenedione levels in phase 2 trials involving patients with CAH.
METHODS: In this phase 3 trial, we randomly assigned adults with CAH in a 2:1 ratio to receive crinecerfont or placebo for 24 weeks. Glucocorticoid treatment was maintained at a stable level for 4 weeks to evaluate androstenedione values, followed by glucocorticoid dose reduction and optimization over 20 weeks to achieve the lowest glucocorticoid dose that maintained androstenedione control (≤120% of the baseline value or within the reference range). The primary efficacy end point was the percent change in the daily glucocorticoid dose from baseline to week 24 with maintenance of androstenedione control.
RESULTS: All 182 patients who underwent randomization (122 to the crinecerfont group and 60 to the placebo group) were included in the 24-week analysis, with imputation of missing values; 176 patients (97%) remained in the trial at week 24. The mean glucocorticoid dose at baseline was 17.6 mg per square meter of body-surface area per day of hydrocortisone equivalents; the mean androstenedione level was elevated at 620 ng per deciliter. At week 24, the change in the glucocorticoid dose (with androstenedione control) was -27.3% in the crinecerfont group and -10.3% in the placebo group (least-squares mean difference, -17.0 percentage points; P<0.001). A physiologic glucocorticoid dose (with androstenedione control) was reported in 63% of the patients in the crinecerfont group and in 18% in the placebo group (P<0.001). At week 4, androstenedione levels decreased with crinecerfont (-299 ng per deciliter) but increased with placebo (45.5 ng per deciliter) (least-squares mean difference, -345 ng per deciliter; P<0.001). Fatigue and headache were the most common adverse events in the two trial groups.
CONCLUSIONS: Among patients with CAH, the use of crinecerfont resulted in a greater decrease from baseline in the mean daily glucocorticoid dose, including a reduction to the physiologic range, than placebo following evaluation of adrenal androgen levels. (Funded by Neurocrine Biosciences; CAHtalyst ClinicalTrials.gov number, NCT04490915.).
The invention belongs to the field of traditional Chinese medicine, and particularly relates to a hemostatic traditional Chinese medicine composition and application thereof. The hemostatic traditional Chinese medicine composition comprises the following raw materials in parts by weight: carbonized human hair 5-20, carbonized Pollen Typhae 10-20, and carbonized Rheum officinale. The formulation is simple, only three traditional Chinese medicinal raw materials are used for compounding, and good properties of raw materials and complementary effect thereof are fully utilized, resulting in a distinct drug effect. The hemostatic traditional Chinese medicine composition has effects of stopping bleeding, promoting tissue regeneration, supporting healthy energy, and the like, and reduces cost. The hemostatic prepared based on the composition is convenient in application, has good hemostatic effect and no wound infection. The preparation method of the hemostatic prepared based on the composition is simple, and suitable for industrial production.
Successful H. pylori eradication therapy remains a challenge in medical practice. Currently, a PPI - based triple therapy containing clarithromycin, amoxicillin or nitroimidazole given for 7 days is the recommended first line treatment approach with an expected eradication success rate of approximately 80%. As second-line treatment option in case of failure, a RBC-based quadruple therapy is currently recommended curing another 80% of patients, leaving a subset of patients with persistent H. pylori infection. Resistance to fluoroquinolones is low in most countries,hence these compounds are potential candidates for second-line and rescue treatment. The new fluoroquinolone moxifloxacin launched by Bayer in 1999 for the treatment of respiratory tract infections, has a broad antibacterial spectrum comparable to levofloxacin but fewer phototoxic and central nervous system excitatory effects. The possible role of moxifloxacin in H. pylori eradication is since under clinical investigation
Participants will meet once a week for 8 weeks (2.5 hours per session), plus a 4-hour retreat day, to engage in mindfulness meditation exercises. Didactic components will include oral presentations, informational videos, and group discussion. Additionally, daily homework assignments will require participants to engage in guided practices for 30 minutes a day for 5 days a week.
Nowadays, several radiographic techniques are available to investigate the peri-implant bone morphology by two-dimensional radiographs such as panoramic radiography and intraoral radiography, or three-dimensional techniques such as computer tomography and cone beam computer tomography (CBCT) (Harris et al. 2012). CBCT provides high-contrast 3D visualization of bone beds; however, artifacts caused by the metallic character of implants could disguise information around implants. The diagnostic outcomes of CBCT imaging of peri-implant bone loss have been related to the type of study and defect morphology (Pelekos et al., 2018). The ex vivo studies (cadaver models), considering sensitivity and specificity reported good values for both circumferential and infrabony defects but lower for dehiscences (de-Azevedo-Vaz et al., 2013, Kamburoglu et al., 2013). Contrastingly, CBCT imaging for defect analysis in animal studies showed positive correlation with histology but tend to overestimate (Fienitz et al., 2012, Golubovic et al., 2012) or underestimate (Corpas Ldos et al., 2011, Ritter et al., 2014) the size of the defect. This variability in the measurement is mainly dependent on the different configuration, location or size of the defect. and also by the scattering, beam hardening artifacts, energy settings, exposure time, field of view.

Hence, it is aimed at assessing the morphology of the peri-implant defects using CBCT
Repeated dose toxicity studies of 1, 3, and 6 months' duration with telithromycin conducted in rat, dog and monkey showed that the liver was the principal target for toxicity with elevations of liver enzymes and histological evidence of damage. There was evidence of reversibility after cessation of treatment. Plasma exposures based on free fraction of drug at the no observed adverse effect levels ranged from 1 to 10 times the expected clinical exposure.

Phospholipidosis (intracellular phospholipid accumulation) affecting a number of organs and tissues (e.g., liver, kidney, lung, thymus, spleen, gall bladder, mesenteric lymph nodes, GI-tract) has been observed with the administration of telithromycin in rats at repeated doses of 900 mg/m2/day (1.8× the human dose) or more for 1 month, and 300 mg/m2/day (0.61× the human dose) or more for 3–6 months. Similarly, phospholipidosis has been observed in dogs with telithromycin at repeated doses of 3000 mg/m2/day (6.1× the human dose) or more for 1 month and 1000 mg/m2/day (2.0× the human dose) or more for 3 months. The significance of these findings for humans is unknown.

Pharmacology/toxicology studies showed an effect both in prolonging QTc interval in dogs in vivo and in vitro action potential duration (APD) in rabbit Purkinje fibers. These effects were observed at concentrations of free drug at least 8.8 (in dogs) times those circulating in clinical use. In vitro electrophysiological studies (hERG assays) suggested an inhibition of the rapid activating component of the delayed rectifier potassium current (IKr) as an underlying mechanism.
Coronary artery bypass is the gold standard surgical treatment of patients with complex coronary disease. It is a common operation and more than 16000 procedures per year are carried out in the UK. Recent publications suggest that during the bypass procedure both left and right internal mammary arteries should be used to bypass coronary stenoses. It was noted that using both internal mammary arteries will result in even better long term survival with improved freedom from cardiac events such as myocardial infarction or further coronary intervention than using. The major drawback of using both internal mammary arteries is the increased risk of sternal wound infection and breakdown. The investigators will use Near Infra-Red Spectroscopy (NIRS) to assess the wound edge oxygenation delivery. The NIRS INVOS system the investigators use within Sheffield Teaching Hospitals can measure oxygenation of soft tissue to a certain depth making it suitable for the assessment of wound edge oxygen delivery. Prevena is commercially available and has a CE mark.

The Prevena wound management system differs from conventional wound dressings, it applies negative pressure to the closed wound for 7 days. Wound complications/infections are decreased when this type of wound management system is used. Studies suggest that Prevena achieves these outcomes because of an increase of perfusion in the wound edges and keeping the wound dry. Patients will be randomised to either the Prevena wound management or their standard of care NHS wound management for their procedure. The oxygenation and outcomes of the wounds will be compared through data collection and the patients followed up during their routine inpatient care and 6 week outpatient appointment.
Fasiglifam 50 mg, tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Sitagliptin placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Metformin ≥1500 mg or Maximum Tolerated Dose (MTD) needs to continue at a stable dose.
HLA A2 positive patients are treated with PADRE and oncopeptide pulsed DC; p53, survivin and telomerase peptides. Each patient is given 6 immunizations with at least 5x106 peptide/lysate pulsed autologous DC. Vaccination 1-4 is given weekly and 4-6 at 2-week intervals. Those patients who exhibit stable disease, partial response or complete response after 6 injections will be given 4 more vaccinations at 2-week interval. The vaccine is applied by either intranodal or intradermal injection near the inguinal region. For adjuvant used IL-2 2 MIU sc. day 2-6. Scans and re-staging tests are performed at scheduled intervals throughout the study.
1. Technical Result Widening of assortment of means for treatment and prophylactics of osteoporosis. 2. Essence The present invention relates to a pharmaceutical formulation of a calcium salt and a dry plant extract in the form of a coated tablet. The composition comprises a core of at least one dry plant extract, enveloped by at least one coating of at least one calcium salt. The plant extracts for the core may be selected from: Vitex agnus castus, Belamcanda chinensis, Cimicifuga racemosam, Trifolium pratense L., Oenothera biennis hom., Glycine soja, Serenoa repens, Urtica dioica, in particular its root; Cucurbita pepo, in particular its seed; Pygeum africanum; as well as suitable mixtures of these. 3. Field of Application Medicine.
Methods, devices, and systems for solving the problem of management and tracking of collection, processing, and movement of biological samples during clinical trials are disclosed herein. According to one embodiment, a method is implemented on one or more servers. The method includes receiving first biological sample data from a first mobile device. The first mobile device includes a camera for capturing at least a portion of the first biological sample data and a first graphical user interface (GUI) configured for displaying the first biological sample data. The method further includes storing the first biological sample data within a distributed ledger. The distributed ledger may include at least one block chain.
A new application of gemfibrozil relates to the field of brain glioma treatment. The application of gemfibrozil disclosed by the invention in improving the treatment effect of temozolomide on brain glioma. The gemfibrozil provided by the invention is applied to enhancing the killing effect of temozolomide on brain glioma cells. The invention relates to a pharmaceutical composition for preventing and/or treating brain glioma, which contains gemfibrozil and temozolomide. Experiments prove that the gemfibrozil can improve the treatment effect of temozolomide on brain glioma, has the function of killing brain glioma cells by cooperating with temozolomide and can enhance the killing effect of temozolomide on brain glioma cells. The gemfibrozil and the temozolomide are prepared into the medicine for preventing and/or treating the brain glioma, and the treatment effect of the temozolomide on the brain glioma can be improved. The application of the gemfibrozil in the preparation of the medicine for preventing and/or treating the brain glioma opens up the new application of the gemfibrozil, and provides a new treatment method and a new treatment scheme for treating the refractory brain glioma.
Participants in Arm II will attend the routine health education by the nurse. The number of participants in group session will be 20 participants per group.
PURPOSE:To obtain an agent for suppressing the proliferation of vascular endothelial cell, having suppressing action to the proliferation of vascular endothelial cell and useful for the treatment of malignant tumor, etc., by using hyaluronic acid or its salt having a specific molecular weight as an active component. CONSTITUTION:Hyaluronic acid or its salt (e.g. sodium salt or potassium salt) having a molecular weight of 50,000-3,000,000 is used as an active component. The molecular weight of the hyaluronic acid or its salt is preferably 500,000-1,800,000. The dose is preferably 0.2-5mg daily for adult in the case of using as an instillation. In the case of using the agent as an injection, it is preferably administered at a rate of 25-250mg of the active component per dose by single injection or by dripping. The hyaluronic acid having a molecular weight of 50,000-3,000,000 can be produced by subjecting a chicken comb to digestion with protease, precipitation with cetylpyridinium chloride and fractionation with ethanol.
To provide compositions and methods for immunotherapy profiling.SOLUTION: Compositions and methods for pharmacodynamic monitoring of immunotherapy are provided herein. The compositions include an immunotherapeutic agent linked to protease substrates. Upon administration, the compositions target sites of disease where proteases are upregulated during responsive immunotherapy, and subsequently cleave the attached substrates. Cleavage fragments are detected in a sample from the body, and detection of the fragments is indicative of an effect of the immunotherapeutic agent. In one embodiment, the therapeutic agent is an immune checkpoint inhibitor such as an anti-PD1 or anti-CTLA4 antibody. The protease substrate can also include a quencher molecule and fluorescent molecule flanking the substrate. In one embodiment, the detectable signal is a peptide fragment of the protease.SELECTED DRAWING: None
Subject matter of the present invention is a lyophilized kit formulation for the preparation of radiometal labeled chelate-functionalized GRP receptor targeting conjugates comprising ? a chelate-functionalized GRP receptor targeting conjugate comprising i. a chelating moiety ii. at least one targeting moiety, wherein said targeting moiety is a GRP receptor (GRPr) targeting peptide, and iii. optionally, at least one linker, connecting the chelating moiety with the GRP receptor (GRPr) targeting moiety, and ? at least one GRP receptor (GRPr) targeting moiety, ? at least one non-reducing sugar selected from the group comprising trehalose and sucrose, and ? at least one radio stabilizer, selected from the group comprising ascorbic acid, ascorbic acid salts, gentisic acid, gentisic acid salts, or mixtures thereof.
In this group, patients will receive placebo talocrural joint manipulation. The application will be similar to that in the experimental group, however, hands will be positioned to avoid creating traction or manipulation force, and this position will be maintained for 20 seconds.
Participants in the Dose Escalation phase will receive HER3-DXd IV Q3W + osimertinib PO once daily. The dose of HER3-DXd in the first cohort will be 3.2 mg/kg Q3W. The dose of osimertinib in the first cohort will be 80 mg PO once daily.
No information is available on a specific result of overdose with erythromycin ethylsuccinate and sulfisoxazole acetyl for oral suspension. Overdosage of erythromycin should be handled with the prompt elimination of unabsorbed drug and all other appropriate measures. Erythromycin is not removed by peritoneal dialysis or hemodialysis.

The amount of a single dose of sulfisoxazole that is either associated with symptoms of overdosage or is likely to be life-threatening has not been reported. Signs and symptoms of overdosage reported with sulfonamides include anorexia, colic, nausea, vomiting, dizziness, headache, drowsiness and unconsciousness. Pyrexia, hematuria and crystalluria may be noted. Blood dyscrasias and jaundice are potential late manifestations of overdosage.

General principles of treatment include the immediate discontinuation of the drug, instituting gastric lavage or emesis, forcing oral fluids, and administering intravenous fluids if urine output is low and renal function is normal. The patient should be monitored with blood counts and appropriate blood chemistries, including electrolytes. If the patient becomes cyanotic, the possibility of methemoglobinemia should be considered and, if present, the condition should be treated appropriately with intravenous 1% methylene blue. If a significant blood dyscrasia or jaundice occurs, specific therapy should be instituted for these complications. Peritoneal dialysis is not effective, and hemodialysis is only moderately effective in removing sulfonamides.

The acute toxicity of sulfisoxazole in animals is as follows:
A nutritive food dioscorea pig heart containing peltate yam, fresh pig heart, fresh peach kernel, and fresh rehmannia root etc., according to the nutrition characteristics, the character and taste, traits and the rate of its trace elements, amino acids, composes by compatibility inversion method special used for heart. Its characteristic is that in order to promote nutrient absorption in vivo according to characteristics of each component to adopt plant diversity physical and chemical method, to design specific preparing technology and processing, with compatibility balance method to protect the gastrointestinal absorption, to bring active function into full play. The present invention is the first time adopted net density dehydration technique, electrostatic electrolysis technology, soft magnetization technology, and uses traditional Chinese medicine processing technology, dish cooking technology, food can preparation technology and isoflux synthetic technology at the same time, with negative pressure vacuum technology and radiation technology to implement sterilization and preservative treatment. The present invention makes up the defects of traditional formula and preparation process in health food products. The present invention can participate in multi-physicochemical in the body, biochemical metabolism, effectively participate in the amino acid synthesis and decomposition, enhance protein biological activity, advance the impact of glutamic acid and tryptophan, promote central neurotransmitter synthesis and degradation, Enhance heart contractility and energy and oxygen supplying for myocardial, maintenance coronary patency, keep heart activity. The present invention also benefits liver and kidney during biotransformation and metabolism in vivo.
BACKGROUND/OBJECTIVES: The literature on consumption of ultra-processed food (UPF) using the NOVA classification is still limited. Therefore, the aim of the present study was twofold: (i) to compare the UPF consumption, sedentary behaviors, and well-being perception between boys and girls; and (ii) to investigate the association between the UPF consumption and risk of overweight, sedentary behaviors, and well-being in adolescents.
METHODS: The present cross-sectional study comprised a sample of 245 adolescents (131 boys) aged 12-17 years-old (M = 14.20; SD = 1.09). Height and weight were assessed, and subsequently, the BMI was computed; furthermore, total body fat percentage was measured with bioelectrical impedance. Daily consumption of UPF was assessed by the NOVA screener and time spent sedentary was assessed by the Midlands Behavior Health 2024 questionnaire. The Mental Health Continuum-Short Form (MHC-SF) was used to measure adolescents' psychosocial well-being. Pearson's correlations and logistic regression analysis were used, controlling for biological, behavioral, and socio-economic confounders.
RESULTS: No sex differences were observed for the different UPF NOVA subscales. Boys reported higher computer use levels than girls on the weekend (p = 0.025), and they spent more time playing electronic games during the week (p = 0.005) and on the weekend than their female counterparts (p < 0.001). Moreover, boys reported higher scores in all well-being dimensions (p < 0.001) than girls.
CONCLUSIONS: The findings revealed, after controlling for sex, sedentary time, and active behaviors, adolescents who consumed UPF on the previous day tended to be associated with a higher risk of being overweight, but also marginally without statistical significance (OR = 0.91, 95% CI: 0.83-1.01, p = 0.06). Of relevance, the present study revealed that both boys and girls of mothers with high educational levels were less likely to be classified as overweight or obese youth.